Claudette E. Loo
YOU?
Author Swipe
View article: TMET-40. Proneural Glioblastomas Exhibit Altered Lipid Metabolism That Promotes Susceptibility to Non-Canonical Cell Death
TMET-40. Proneural Glioblastomas Exhibit Altered Lipid Metabolism That Promotes Susceptibility to Non-Canonical Cell Death Open
Glioblastomas (GBMs) are highly resistant to therapies (e.g., radiation, chemotherapy therapy) targeting canonical apoptotic pathways. Emerging evidence suggests that non-canonical, lipid-mediated cell death mechanisms - such as ferroptosi…
View article: Associations between adipocyte hypertrophy and epithelium-to-stroma proportion with clinicopathologic and epidemiologic factors in women with ductal carcinoma in situ
Associations between adipocyte hypertrophy and epithelium-to-stroma proportion with clinicopathologic and epidemiologic factors in women with ductal carcinoma in situ Open
Background Ductal carcinoma in situ (DCIS), a non-obligate precursor of invasive breast cancer (IBC), presents a clinical dilemma due to the risk of overtreatment. Histopathological features such as adipocyte hypertrophy and epithelium-to-…
View article: Iodine Seed−Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer
Iodine Seed−Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer Open
Importance Most patients with clinically node-positive (cN + ) breast cancer receive primary systemic treatment (PST) followed by axillary lymph node dissection (ALND) and/or locoregional radiation (RT). The necessity of axillary treatment…
View article: 193MO Predictive value of FDG-PET/CT and MRI for neoadjuvant immunotherapy (IO) response in early-stage triple-negative breast cancer (eTNBC): Exploratory analysis of the phase II BELLINI trial
193MO Predictive value of FDG-PET/CT and MRI for neoadjuvant immunotherapy (IO) response in early-stage triple-negative breast cancer (eTNBC): Exploratory analysis of the phase II BELLINI trial Open
View article: Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol
Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol Open
Omission of ALND after PST in breast cancer patients with extensive nodal involvement who achieve pCR of the MARI node is associated with excellent five-year oncologic outcome.
View article: Supine Versus Prone: A Comparison of Percutaneous Nephrolithotomy Outcomes in Obese Patients
Supine Versus Prone: A Comparison of Percutaneous Nephrolithotomy Outcomes in Obese Patients Open
View article: High-impact complications after breast cancer surgery in the Dutch national quality registry: evaluating case-mix adjustment for hospital comparisons
High-impact complications after breast cancer surgery in the Dutch national quality registry: evaluating case-mix adjustment for hospital comparisons Open
Background Comparison of quality indicators can improve quality of care. However, case-mix adjustment is deemed essential. The aim of this study was to develop and validate case-mix adjustment models and to evaluate the effect of case-mix …
View article: The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy
The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy Open
Purpose This study aims to identify which breast cancer patients benefit from the routine use of FDG-PET/CT in a large cohort of patients scheduled for neoadjuvant systemic therapy (NST). Methods A total of 1337 breast cancer patients elig…
View article: Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial Open
View article: Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer
Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer Open
Purpose Breast cancer (BC) patients undergoing FDG-PET/CT scans for neoadjuvant chemotherapy (NAC) may have additional non-BC related findings. The aim of this study is to describe the clinical implications of these findings. Methods We in…
View article: Intraoperative near infrared functional imaging of rectal cancer using artificial intelligence methods - now and near future state of the art
Intraoperative near infrared functional imaging of rectal cancer using artificial intelligence methods - now and near future state of the art Open
View article: Re-attendance in supplemental breast MRI screening rounds of the DENSE trial for women with extremely dense breasts
Re-attendance in supplemental breast MRI screening rounds of the DENSE trial for women with extremely dense breasts Open
View article: Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature Open
View article: Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis
Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis Open
View article: High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial Open
View article: 136P Clinical implications of non-breast cancer related findings in breast cancer patients undergoing PET/CT scan prior to neoadjuvant systemic therapy
136P Clinical implications of non-breast cancer related findings in breast cancer patients undergoing PET/CT scan prior to neoadjuvant systemic therapy Open
Breast cancer patients undergoing PET/CT scans for neoadjuvant systemic therapy may have non-breast cancer (BC) related finding. The aim of this study is to describe the incidence, additional work-up and possible impact of these findings. …
View article: Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial Open
View article: PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial Open
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between …
View article: Supplementary Table S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Table S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Competing risk analysis; Cox proportional hazards models are shown for overall survival, breastâ€�cancer related death, and nonâ€�breast cancer related death. For each model, pooled hazard ratios (HR) and 95% confidence intervals (CI) are …
View article: Supplementary Figure S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Figure S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Hazard raô€†Ÿo of intermediate contralateral parenchymal enhancement (CPE) (yellow) and high CPE (green) with respect to low CPE. CPE was calculated as the average of the late enhancement values above the threshold. CPE groups were subsequ…
View article: Data from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Data from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Purpose: To determine whether markers of healthy breast stroma are able to select a subgroup of patients at low risk of death or metastasis from patients considered at high risk according to routine markers of the tumor.Experimen…
View article: Data from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Data from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Purpose: To determine whether markers of healthy breast stroma are able to select a subgroup of patients at low risk of death or metastasis from patients considered at high risk according to routine markers of the tumor.Experimen…
View article: Supplementary Table S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Table S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Competing risk analysis; Cox proportional hazards models are shown for overall survival, breastâ€�cancer related death, and nonâ€�breast cancer related death. For each model, pooled hazard ratios (HR) and 95% confidence intervals (CI) are …
View article: Supplementary Figure S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Figure S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Hazard raô€†Ÿo of intermediate contralateral parenchymal enhancement (CPE) (yellow) and high CPE (green) with respect to low CPE. CPE was calculated as the average of the late enhancement values above the threshold. CPE groups were subsequ…
View article: Predicting breast cancer types on and beyond molecular level in a multi-modal fashion
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion Open
View article: Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study Open
View article: 110P An in-depth analysis of pathology results of surgical specimen and biopsies performed after NST in an attempt to identify patients with pCR: Time to reconsider the omission of surgery?
110P An in-depth analysis of pathology results of surgical specimen and biopsies performed after NST in an attempt to identify patients with pCR: Time to reconsider the omission of surgery? Open
View article: Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol Open
View article: Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review
Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review Open
View article: Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients Open